Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$18.08 - $25.38 $17,881 - $25,100
-989 Reduced 3.22%
29,735 $690,000
Q2 2024

Aug 13, 2024

BUY
$24.35 - $44.39 $748,129 - $1.36 Million
30,724 New
30,724 $748,000
Q3 2023

Jun 03, 2024

SELL
$25.44 - $37.35 $26,508 - $38,918
-1,042 Reduced 2.5%
40,659 $1.04 Million
Q3 2023

Oct 10, 2023

SELL
$25.44 - $37.35 $26,508 - $38,918
-1,042 Reduced 2.5%
40,659 $1.04 Million
Q2 2023

Jun 03, 2024

SELL
$23.94 - $32.36 $370,303 - $500,544
-15,468 Reduced 27.06%
41,701 $1.2 Million
Q2 2023

Jul 24, 2023

SELL
$23.94 - $32.36 $370,303 - $500,544
-15,468 Reduced 27.06%
41,701 $1.2 Million
Q1 2023

Jun 03, 2024

BUY
$14.72 - $23.97 $841,527 - $1.37 Million
57,169 New
57,169 $1.37 Million
Q1 2023

Apr 12, 2023

SELL
$14.72 - $23.97 $127,902 - $208,275
-8,689 Reduced 13.19%
57,169 $1.37 Million
Q4 2022

Feb 14, 2023

SELL
$14.14 - $23.06 $98,895 - $161,281
-6,994 Reduced 9.6%
65,858 $1.12 Million
Q3 2022

Nov 04, 2022

SELL
$13.05 - $22.13 $51,651 - $87,590
-3,958 Reduced 5.15%
72,852 $1.08 Million
Q2 2022

Jul 27, 2022

BUY
$12.26 - $31.17 $469,643 - $1.19 Million
38,307 Added 99.49%
76,810 $1.21 Million
Q1 2022

May 13, 2022

SELL
$17.64 - $39.57 $26,724 - $59,948
-1,515 Reduced 3.79%
38,503 $1.04 Million
Q4 2021

Feb 14, 2022

SELL
$34.2 - $47.56 $5,095 - $7,086
-149 Reduced 0.37%
40,018 $1.48 Million
Q3 2021

Oct 29, 2021

BUY
$27.88 - $58.25 $28,298 - $59,123
1,015 Added 2.59%
40,167 $1.92 Million
Q2 2021

Aug 06, 2021

BUY
$25.79 - $42.11 $1.01 Million - $1.65 Million
39,152 New
39,152 $1.33 Million

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $480M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Vontobel Holding Ltd. Portfolio

Follow Vontobel Holding Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Vontobel Holding Ltd. with notifications on news.